The $12 million upfront payment RedHill Biopharma Ltd. (NASDAQ: RDHL) made to acquire exclusive commercialization rights to Rebyota and Clenpiq from Ferring Pharmaceuticals looks lean against the products' combined approximately $37.5 million in U.S. net sales in 2025. The risk is that what RedHill actually retains, after royalties of 5% to 20% of net sales, undisclosed inventory commitments, and contingent payments, has not been made visible.
The case for the deal turns on what the existing accounts already show. Rebyota, FDA-approved to prevent recurrent Clostridioides difficile infection in adults following antibiotic treatment, generated approximately $16.9 million in U.S. net sales last year across about 600 active accounts. Clenpiq, a ready-to-drink bowel preparation for colonoscopy in adults and pediatric patients aged nine and older, produced $20.6 million with what RedHill described as minimal promotion. Both products can be run through an existing commercial infrastructure without requiring new manufacturing assets. Ferring Pharmaceuticals continues to produce and supply the products under a 13-year initial term that renews automatically in two-year periods. RedHill funded the $12 million upfront from the $18 million it received from the Talicia divestiture. If additional promotion lifts Clenpiq's revenue, the commercial team could expand the top line without a proportional increase in fixed costs.
The counterargument is that owning commercialization rights and owning the products are structurally different things, and the difference is material. Royalties on net sales at rates between 5% and 20% reduce what RedHill keeps from every dollar generated. Minimum annual Rebyota purchase commitments run from 2027 through 2029, with amounts not disclosed, and those commitments become a cash liability if demand comes in below plan. RedHill controls the sales effort but not the supply chain. Ferring retains manufacturing, so production disruptions or cost pressures sit outside RedHill's direct control. The company has not disclosed product gross margins, gross-to-net deductions, or expected contribution margins.
On balance, RedHill has added two products with a documented 2025 sales base of $37.5 million for limited upfront cash, and the infrastructure rationale is sound on its face. The read-through to shareholder value rests on product-level margins and supply performance that RedHill has not yet quantified. The line to watch is whether the Rebyota account count grows beyond the current 600 and whether Clenpiq's revenue holds once RedHill commits meaningful commercial resources to it. At the end of the second quarter of 2026, per Insider Monkey's database, one hedge fund held RDHL.